Approved: May 10, 1996.

Stephen D. Potts,

Director, Office of Government Ethics.

[FR Doc. 96–12222 Filed 5–15–96; 8:45 am]

BILLING CODE 6345–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Commission on Dietary Supplement Labels: Meeting No. 4; Opportunity To Provide Comments

AGENCY: Office of Disease Prevention and Health Promotion.

ACTION: Commission on Dietary Supplement Labels: Notice of meeting #4; Opportunity to provide comments.

SUMMARY: The Department of Health and Human Services (HHS) is (a) providing notice of the fourth meeting of the Commission on Dietary Supplement Labels, and (b) soliciting oral and written comments.

DATES: (1) The Commission will meet June 6, 1996, from 8:30 a.m. to 4:30 p.m. Eastern Daylight Time at the Clarion Plaza Hotel, 9700 International Drive, Orlando, Florida 32819–8114; (2) Written comments on the scope and intent of the Commission's objectives may be submitted by 5:00 p.m. E.D.T. on June 30, 1996 to the address noted below.

FOR FURTHER INFORMATION CONTACT: Kenneth D. Fisher, Ph.D., Executive Director, Commission on Dietary Supplement Labels, Office of Disease Prevention and Health Promotion, Room 738G, Hubert Humphrey Building, 200 Independence Ave. S.W., Washington, D.C. 20201, (202) 690–7102.

SUPPLEMENTARY INFORMATION:

Commission's Task

Public Law 103–417, Section 12, authorized the establishment of a Commission on Dietary Supplement Labels whose seven members have been appointed by the President. The appointments to the Commission by the President and the establishment of the Commission by the Secretary of Health and Human Services reflect the commitment of the President and the Secretary to the development of a sound and consistent regulatory policy on labeling of dietary supplements.

The Commission is charged with conducting a study and providing recommendations for regulation of label claims and statements for dietary supplements, including the use of supplemental literature in connection with their sale and, in addition, procedures for evaluation of label claims. The Commission is expected to evaluate how best to provide truthful, scientifically valid, and nonmisleading information to consumers in order that they may make informed health care choices for themselves and their families. The Commission's study report may include recommendations on legislation, if appropriate and necessary.

Announcement of Meeting

The Commission's fourth meeting will be June 6, 1996, 8:30 a.m. to 4:30 p.m. Eastern Daylight Time. The meeting will be held in the Salon Room at the Clarion Plaza Hotel, 9700 International Drive, Orlando, Florida 32819–8114. The agenda will include (a) oral comments from interested parties and the general public, (b) identification of additional information needs, and (c) discussion of dietary supplement label information.

Public Participation at Meeting

The meeting is open to the public. However, space is limited. Both oral and written comments from the public will be accepted, but oral comments at the meeting will be limited to a maximum of five minutes per presenter; thus, organizations and persons wishing to make their views known to the Commission should use the time for oral presentation to summarize their written comments. Persons and organizations that have not made presentations or submitted statements previously will be given preference on the agenda. Members of the Commission may wish to question the presenters following each oral presentation. Please request the opportunity to present oral comments in writing and provide fifteen (15) copies of the written comments from which the oral presentation is abstracted to the address above by May 29, 1996. If you will require a sign language interpreter, please call Sandra Saunders (202) 690–7102 by 4:30 p.m. E.D.T. on May 29, 1996.

Written Comments

By this notice, the Commission is soliciting submissions of written comments, views, information, and data pertinent to the Commission's task. Comments should be sent to Kenneth D. Fisher, Ph.D., Executive Director of the Commission at the Office of Disease Prevention and Health Promotion, Room 738G, Hubert Humphrey Building, 200 Independence Ave. S.W., Washington, D.C. 20201, by 5:00 p.m. E.D.T. on June 30, 1996.

Dated: May 8, 1996.

Claude Earl Fox,

Deputy Assistant Secretary for Health (Disease Prevention and Health Promotion), Department of Health and Human Services.

[FR Doc. 96–12223 Filed 5–15–96; 8:45 am]

BILLING CODE 4160–17–M

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following case:

Michael W. Washabaugh, Ph.D., Johns Hopkins University: Based on an investigation conducted by the institution as well as information obtained by ORI during its oversight review, ORI found that Michael W. Washabaugh, Ph.D., Associate Professor of Biochemistry, Department of Biochemistry, Johns Hopkins University School of Hygiene and Public Health, committed scientific misconduct by reporting falsified and/or fabricated research data in two grant applications submitted to the National Institutes of Health.

Specifically, Dr. Washabaugh (1) reported falsified results of experiments concerning the number of DTNB (5,5′-dithiobis [2-nitrobenzoate]) reactive thiols in native thiamin binding protein in a grant application entitled ''Mechanism of a periplasmic permease,'' and (2) reported falsified and/or fabricated portions of data presented in two separate figures to support his hypothesis of thiamin binding to thiamin binding protein in grant applications entitled ''Mechanism of a periplasmic permease'' and ''Mechanisms of enzymic and non-enzymic thiamin reactions.''

Dr. Washabaugh has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the four (4) year period beginning May 7, 1996, to exclude himself from:

(1) Any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 C.F.R. Part 76 (Debarment Regulations), and

(2) Serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.